To appreciate why this discovery matters, it helps to recall what p53 actually does. Often called the guardian of the genome, p53 sits at the center of a vast cellular decision network, determining whether a stressed cell should pause and repair its DNA, permanently stop dividing, or initiate its own destruction. When p53 malfunctions, the consequences can be catastrophic: uncontrolled cell division leads to cancer, while excessive p53 activity has been linked to degenerative conditions and premature aging. Because the stakes are so high, the TP53 gene is among the most complexly regulated in the human genome. It encodes at least ten different RNA variants and, until now, twelve widely accepted protein forms, each generated through alternative promoters, splicing patterns, or translation start sites. The sheer diversity of these forms reflects the gene’s central role in orchestrating cellular fate, and each new isoform discovered offers a fresh window into how that orchestration is fine-tuned.

The newly identified Δ246p53 arises through a mechanism known as alternative translation initiation. Rather than being produced from a separate RNA transcript, it is translated from the same messenger RNA that makes full-length p53, but the protein-building machinery of the cell starts reading at a different point: codon 246. This internal starting signal, or translation initiation site, is preceded by a strong Kozak sequence, a consensus motif that ribosomes recognize as an efficient place to begin protein synthesis. The result is a truncated protein that lacks the first 245 amino acids of the full-length protein but retains the critical DNA-binding domain and the C-terminal region. Remarkably, when the researchers compared TP53 sequences across vertebrate species, they found that this internal initiation site and its surrounding Kozak context are conserved all the way from sea lamprey, one of the most primitive living vertebrates, to humans. Such deep evolutionary conservation is a strong hint that the production of Δ246p53 is not random noise but a feature that natural selection has preserved for hundreds of millions of years.

One of the greatest challenges in studying small protein isoforms is proving that they genuinely exist in cells rather than appearing only under artificial laboratory conditions. The team, led by Shrutee N. Parkar and Marco M. Candeias of Kyoto University’s Graduate School of Medicine, together with colleagues at the National Institute of Health Doutor Ricardo Jorge, the University of Lisbon, the University of Coimbra, and the University of Trento, mounted an unusually rigorous verification campaign. They introduced frameshift mutations and start codon mutations into the TP53 sequence and showed that these alterations abolished production of the 18-kilodalton protein, confirming that translation truly begins at codon 246. They then detected Δ246p53 using five different antibodies, each recognizing a distinct epitope spanning from the N-terminus to the C-terminus of the protein. Critically, an antibody raised against a region of the DNA-binding domain just upstream of the new initiator methionine, a region that Δ246p53 by definition does not contain, failed to detect the protein, serving as an elegant negative control.

The researchers went further, deploying genetic tools that specifically silenced the new isoform without touching the full-length protein. Small interfering RNAs and an antisense oligonucleotide designed to target the translation initiation site at codon 246 knocked down Δ246p53 levels while leaving full-length p53 largely unaffected. This selective knockdown is technically significant because it demonstrates that the two protein forms can be independently manipulated, opening the door to functional studies that would otherwise be impossible. Together, the mutation analysis, the multi-antibody validation, and the targeted silencing build a case for the existence of Δ246p53 that is difficult to dismiss, meeting a standard of evidence that has sometimes been lacking in earlier reports of p53 isoforms.

Having established that Δ246p53 is real, the team turned to the question of what it does. The answer, in short, is that it behaves like a damage-activated amplifier of the p53 family’s senescence program. When cells were exposed to DNA-damaging agents, levels of Δ246p53 rose, indicating that the isoform is part of the cellular response to genotoxic stress. In colony formation assays, a standard test of a cell’s ability to proliferate and form visible colonies, the presence of Δ246p53 impaired tumor formation and growth, and the isoform triggered cellular senescence, the state of permanent proliferative arrest that stops potentially malignant cells in their tracks. These observations position Δ246p53 as a tumor-suppressive factor in its own right, capable of reinforcing the growth-arrest decisions that full-length p53 makes under stress.

The mechanistic story that emerged from the study is particularly intriguing because Δ246p53 does not simply mimic the full-length protein. Instead, it engages in two distinct interactions with different members of the p53 protein family. First, Δ246p53 physically interacts with full-length p53 itself. This interaction leads to a decrease in the expression of two well-known p53 target genes: HDM2, the negative feedback regulator that normally keeps p53 in check, and p21, the cyclin-dependent kinase inhibitor that executes cell cycle arrest. The reduction of these targets suggests that Δ246p53 modulates, rather than merely duplicates, the canonical p53 transcriptional program, potentially reshaping the balance of the feedback loops that govern p53 activity in damaged cells.

Second, and perhaps more surprisingly, Δ246p53 interacts with ΔNp63, an isoform of p63, a close evolutionary relative of p53 that plays essential roles in epithelial development and tumor suppression. Through this interaction, Δ246p53 enables the activation of p21 in a manner that depends on p63 rather than on p53. This p53-independent route to p21 induction is a significant conceptual advance, because p21 has long been viewed primarily as a direct transcriptional target of p53. The finding that a small p53 isoform can act as a bridge, recruiting the p63 pathway to drive p21 expression and thereby promote senescence, reveals an unexpected layer of crosstalk within the p53 family. It suggests that the family members, which include p53, p63, and p73, do not operate as parallel branches but can be physically and functionally coupled through their shorter isoforms in ways that biologists are only beginning to map.

The broader implications of the work extend in two directions at once, and both are likely to energize the field. On the cancer side, Δ246p53’s ability to impair tumor formation and growth marks it as a potential ally of tumor suppression, and understanding how its production is regulated could reveal vulnerabilities in cancers that evade senescence. On the aging side, senescence is a double-edged sword: while it protects against cancer in the young, the accumulation of senescent cells over a lifetime contributes to tissue degeneration and chronic inflammation, a phenomenon now widely studied under the banner of cellular aging. A naturally occurring factor that specifically promotes senescence through p21 regulation could therefore be a key to understanding, and perhaps eventually controlling, the trade-off between cancer prevention and aging that p53 sits at the heart of. As the authors note, future studies of Δ246p53 are likely to deepen our grasp of both tumor suppression and the biology of growing old.

There is also a methodological lesson embedded in this discovery. Δ246p53 was hiding in plain sight within one of the most intensively studied genes in biology, detectable only through careful attention to translation start sites and the use of antibodies mapped to precise epitopes. The fact that its initiating codon is conserved from sea lamprey to humans implies that other conserved internal initiation sites may lurk within the p53 family and beyond, waiting to be uncovered by similar approaches. For a gene that has been examined by tens of thousands of laboratories over more than four decades, the emergence of a thirteenth protein form is a humbling reminder that even the most familiar molecular landscapes still hold surprises. The identification of Δ246p53 does not rewrite the p53 story, but it adds an entirely new chapter, one that connects translation control, protein family crosstalk, and the ancient cellular decision to stop dividing in the face of damage.

Subject of Research: Discovery of the Δ246p53 protein isoform and its role in DNA damage response and cellular senescence

Article Title: New Δ246p53 isoform responds to DNA damage to enhance p53 family functions in cellular senescence

Article References: Parkar, S. N., Ramalho, A. C., López-Iniesta, M. J., Silva, R., Zhao, J., Kimura, K., Dassi, V., da Silva Rita, F., Ciribilli, Y., Bisio, A., Romão, L., & Candeias, M. M. (2026). New Δ246p53 isoform responds to DNA damage to enhance p53 family functions in cellular senescence. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03374-7

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03374-7

Keywords: p53, Δ246p53, protein isoform, DNA damage, cellular senescence, tumor suppression, p21, ΔNp63, alternative translation initiation, TP53, aging, cancer biology

Researchers at Heinrich-Heine-University Düsseldorf, led by Dennis Sohn and colleagues, report that pediatric medulloblastoma cells carrying functional, wild-type p53 do not simply die when bombarded with gamma irradiation. Instead, many of them enter senescence, a terminal and stable arrest of the cell cycle. These zombie-like cells stop dividing but refuse to die, lingering in the tissue for weeks. Crucially, the team showed that these irradiated, senescent tumor cells can then be selectively wiped out with senolytic drugs—compounds designed to eliminate senescent cells. The finding opens a potential two-step strategy: radiation first drives susceptible tumor cells into senescence, and senolytics then clear them away.

The study compared two SHH-activated medulloblastoma cell lines with fundamentally different genetic backgrounds. ONS76 cells carry wild-type p53, the master tumor suppressor that decides a cell’s fate after catastrophic DNA damage. UW228-3 cells carry a mutated, dysfunctional p53. When both lines were exposed to a 20 Gy dose of gamma irradiation, their responses diverged dramatically. UW228-3 cells detached from the culture dish and degraded completely within three to seven days. ONS76 cells, by contrast, remained attached for more than fifty days, flattening out and swelling enormously in both cell body and nucleus—classic hallmarks of senescence.

The molecular evidence followed the morphology. Irradiated ONS76 cells showed a dose-dependent stabilization of p53 and a strong increase in p21, the cyclin-dependent kinase inhibitor encoded by the CDKN1A gene that enforces the senescence arrest. They also accumulated senescence-associated beta-galactosidase activity, a lysosomal enzyme widely used as a senescence marker, and built up lipofuscin, the pigment-like cellular debris characteristic of aged or senescent cells. When the researchers knocked down p53 or p21 using siRNAs, the senescence program collapsed: far fewer cells became senescent and substantially more died instead. This established that radiation-induced senescence in these cells is strictly p53/p21-dependent.

The p53-mutated UW228-3 cells told the opposite story. They showed only a faint, transient rise in beta-galactosidase activity and never developed senescent morphology. Instead, measurements of lactate dehydrogenase release—a marker of plasma membrane destruction—and of DEVDase-like caspase activity revealed that they died by apoptosis, the controlled self-destruction pathway. A pan-caspase inhibitor, q-VD-OPh, completely abolished this cell death while leaving senescence untouched in the wild-type line. The team also employed a recently developed fluorescent lipofuscin binder, GLF16, alongside the amine-reactive viability dye Zombie-violet, allowing simultaneous flow cytometric quantification of senescent and dead cells with sharper discrimination than traditional staining.

The researchers then turned to c-Myc, a proto-oncogene that serves as a crucial negative prognostic factor in medulloblastoma and is known to antagonize p21. Using engineered ONS76 and UW228-3 lines that constitutively overexpress c-Myc, they found that the oncogene tipped the balance away from senescence. In irradiated ONS76/c-Myc cells, p21 protein levels dropped—though p21 mRNA levels did not, indicating that c-Myc interferes with p21 protein production or stability rather than its transcription. Fewer cells adopted senescent morphology, and more cells died, a death that q-VD-OPh could block even though it was not accompanied by elevated caspase activity. Notably, this c-Myc effect operated independently of p53 status. The senescent population in c-Myc-overexpressing cells also proved far more resistant to senolytic treatment, underscoring how oncogene dosage can shape therapeutic vulnerability.

The therapeutic payoff came in the final set of experiments. Seven days after irradiation, when the ONS76 cultures had become fully senescent, the researchers treated them with four senolytic compounds: the BCL-2 family inhibitors Navitoclax and Venetoclax, and the PI3K inhibitors PX-866 and BAY 80-6946 (Copanlisib), the latter already FDA-approved. All four killed the senescent cells in a dose-dependent manner. Navitoclax, however, also eliminated proliferating cells at the highest concentration tested, 30 µM—a reminder of the well-known toxicity problem that has complicated its clinical use, since healthy non-senescent cells are targeted at higher doses. The PI3K inhibitors, by contrast, showed a cleaner specificity for the senescent population.

The clinical logic behind this approach is compelling. Medulloblastoma is unusual among cancers in that relatively few tumors harbor p53 mutations, and in the SHH-activated subtype, p53 status actually defines two distinct risk groups: p53-mutated tumors carry a five-year overall survival of roughly 41 percent and are classified as high risk, while p53 wild-type tumors fare far better at about 81 percent. The new findings suggest that these two groups respond to radiotherapy in mechanistically different ways—senescence in the wild-type setting, apoptosis in the mutated one—a distinction invisible to standard proliferation-based cytotoxicity assays. Senolytic combination therapy would therefore primarily apply to the intermediate-risk, p53 wild-type group, where it could potentially improve outcomes further while reducing the radiation dose needed for tumor control.

The broader context strengthens the case. Senescent cells are not inert; they secrete a cocktail of cytokines and chemokines known as the senescence-associated secretory phenotype, or SASP, which drives chronic tissue microinflammation and can support tumor relapse. Craniospinal irradiation is associated with accelerated brain aging in survivors, and studies in glioblastoma have already shown that eliminating therapy-induced senescent cells with Navitoclax attenuates recurrence. Mouse studies of whole-brain irradiation likewise suggest that senolytic clearance protects cognitive function and the blood-brain barrier. Because senescence can be triggered at lower radiation doses than outright cell death, pairing senolytics with craniospinal irradiation might one day allow clinicians to cure tumors with less radiation exposure while simultaneously mopping up the senescent cells that radiation leaves behind.

Important caveats remain. The entire study was conducted in cell lines rather than animal models or patients, and the exact nature of the c-Myc-driven, caspase-inhibitable cell death observed in the overexpressing cells is still unclear. The authors themselves note that it would be intriguing to test whether JQ1, a bromodomain inhibitor that suppresses c-Myc signaling, could push c-Myc-high, p53 wild-type medulloblastoma cells back into a senescence-permissive state and thereby restore their susceptibility to senolytics. Still, the work is the first to document radiation-induced senescence in medulloblastoma cells and to demonstrate that these cells can be eliminated with existing senolytic drugs. If the strategy survives translation into preclinical models, it could reshape how one of pediatric oncology’s most grueling treatments is delivered—turning the very cells that radiation strands between life and death into targets for a second, cleaner strike.

Subject of Research: Radiation-induced cellular senescence in pediatric medulloblastoma and its targeting by senolytic drugs

Article Title: p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances

Article References: Sonntag, J., Preugschas, R.-L., Jazmati, D., Qin, N., Neuwahl, J., Matuschek, C., Remke, M., Budach, W., Hörner-Rieber, J., & Sohn, D. (2026). p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances. Cell Death Discovery, 12(1), Article 410. https://doi.org/10.1038/s41420-026-03404-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03404-4

Keywords: medulloblastoma, senescence, senolytics, p53, c-Myc, p21, gamma irradiation, craniospinal irradiation, Navitoclax, PI3K inhibitors, SASP, pediatric brain tumor

The team, led by corresponding author Chunshui Zhou, focused on a small molecule called SMIP004, a compound previously known to act on mitochondria, the energy-producing organelles inside cells. In a small-scale chemical screen run against senescent cancer cells, SMIP004 stood out for its ability to selectively kill TIS cells while sparing normally proliferating ones. That selectivity is the holy grail of senolytic drug development: any agent that clears senescent cells must not simultaneously damage healthy tissue or the still-vulnerable bulk of the tumor. Understanding why SMIP004 showed this preference became the central question of the study, and the answer led the researchers deep into the metabolic rewiring that defines the senescent state.

The key player turned out to be PDHA, the catalytic subunit of the pyruvate dehydrogenase complex, a mitochondrial enzyme that occupies one of the most important crossroads in cellular metabolism. Pyruvate, the end product of glycolysis, stands at a fork in the road: it can be converted to lactate in the cytoplasm, as happens in many cancer cells even in the presence of oxygen, or it can be funneled into the mitochondria by PDHA, feeding the citric acid cycle and oxidative phosphorylation. The researchers discovered that in therapy-induced senescent cancer cells, PDHA protein is unusually stable, and that this stabilization depends on elevated activity of AMPK, the AMP-activated protein kinase that serves as the cell’s master energy sensor. When energy is scarce, AMPK switches on catabolic programs and dials down anabolic ones; in senescent cells, the team found, AMPK activity keeps PDHA protected from degradation, effectively locking the senescent cells into a particular mitochondrial metabolic configuration.

SMIP004, remarkably, does not touch AMPK itself. Instead, the compound promotes the ubiquitin-mediated degradation of PDHA, stripping away the stabilized enzyme and collapsing the metabolic adaptation that senescent cells depend upon. The researchers demonstrated this relationship with elegant complementary experiments. When they activated AMPK with metformin, the widely used diabetes drug, proliferating cells began stabilizing ectopically expressed PDHA — and SMIP004 treatment could reverse that stabilization. Even more decisively, when the team mutated the AMPK phosphorylation sites on PDHA, the stabilization was abolished altogether. Together, these results establish a clean causal chain: AMPK activity stabilizes PDHA through its phosphorylation sites, and SMIP004 short-circuits that protection by pushing PDHA into the degradation machinery, independent of AMPK.

The consequences for senescent cancer cells are catastrophic. With PDHA destabilized, the cells’ mitochondrial metabolism falters, and at low doses SMIP004 induces what the authors describe as an energy crisis, culminating in massive apoptosis. Because senescent cells have become metabolically dependent on the AMPK–PDHA axis, they are far more vulnerable to this disruption than proliferating cells, which retain the flexibility to compensate. This dependency creates a therapeutic window: a dose of SMIP004 that leaves normal dividing cells largely unharmed can wipe out the senescent survivors that chemotherapy leaves behind. It is a textbook example of synthetic lethality emerging from a state-specific metabolic liability — the very principle that has driven success in other areas of targeted cancer therapy.

The most clinically compelling results came from mouse experiments. When the researchers combined SMIP004 with doxorubicin, a mainstay anthracycline chemotherapy drug, the combination suppressed tumor growth more effectively than chemotherapy alone, eliminated p21-positive cells — p21 being a canonical marker of senescence — and reduced metastatic lesions in tumor-bearing animals. This is precisely the outcome a senolytic strategy is designed to achieve: the cytotoxic drug generates the senescent population, and the senolytic agent clears it before those cells can contribute to relapse or spread. The finding that a senolytic can measurably reduce metastatic burden is particularly notable, since metastasis remains the leading cause of cancer mortality and is notoriously difficult to prevent with conventional approaches.

To explore the biology at single-cell resolution, the team performed single-cell RNA sequencing, which revealed that elevated transcription of PDHA is associated with senescence-like tumor cells. This observation ties the protein-level stabilization story to a broader transcriptional program: senescent tumor cells do not merely accumulate PDHA protein through post-translational protection, they also upregulate its expression, suggesting that the enzyme sits at the heart of the senescent phenotype rather than being an incidental passenger. The convergence of transcriptomic and biochemical evidence strengthens the case that PDHA is a genuine vulnerability of TIS cells and not an artifact of a single experimental system.

The human relevance of the findings received support from clinical tissue analysis. The researchers found that the expression of both PDHA and p21 is enhanced in tumors following chemotherapy, and that higher expression of these markers correlates with poor patient survival. In other words, the senescent population the study targets is not a laboratory curiosity — it appears in real patients after real treatment, and its presence tracks with worse outcomes. That correlation does not prove causation, but it is exactly the kind of biomarker evidence that justifies pursuing PDHA-targeted senolytics toward the clinic, and it suggests that PDHA and p21 could serve as pharmacodynamic markers to identify patients most likely to benefit from a combination regimen.

The study also carries broader implications for how scientists think about the metabolic identity of senescent cells. AMPK is often portrayed as a tumor-suppressive, health-promoting signal — metformin’s putative anti-cancer reputation rests partly on AMPK activation — yet this work shows that the same pathway can be co-opted by senescent tumor cells to stabilize a key metabolic enzyme and sustain their survival. The lesson is that context matters enormously: a pathway that protects healthy cells from metabolic stress may simultaneously protect damaged, treatment-altered tumor cells from elimination. It also highlights the value of unbiased chemical screening paired with proteomic analysis, an approach the team pursued with support from the Gygi laboratory’s proteomics expertise at Harvard, which can uncover mechanisms that hypothesis-driven work might never have targeted.

Considerable work remains before SMIP004 or any derivative could reach patients. The compound was identified in a small-scale screen, and its precise molecular target within the ubiquitin degradation machinery, its pharmacokinetic profile, and its safety in combination regimens all require further definition. Dosing in mice will need careful translation, and senolytics as a class raise questions about long-term effects, since senescent cells also play roles in wound healing and tissue repair. Still, the study delivers a complete conceptual arc: a defined metabolic dependency of therapy-induced senescent tumor cells, a small molecule that exploits it through a clearly delineated mechanism, and preclinical evidence that combining the compound with standard chemotherapy improves outcomes while reducing metastasis. If the AMPK–PDHA axis proves to be a general feature of senescent tumor cells across cancer types, the strategy described by Zhou and colleagues could become a template for a new generation of adjuvant therapies — drugs that do not attack the tumor directly, but instead clean up the dangerous residue that treatment leaves behind.

Subject of Research: Selective elimination of therapy-induced senescent tumor cells with the senolytic compound SMIP004 via blockade of AMPK-dependent PDHA stabilization

Article Title: Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy

Article References: Zhang, M., Piao, S., Song, Y., Zhao, N., Liu, A., Fu, S., Sun, W., Qiu, X., Zhang, J., Paulo, J. A., Yang, Y., Gygi, S. P., Xu, H., & Zhou, C. (2026). Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03395-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03395-2

Keywords: senolytics, therapy-induced senescence, SMIP004, PDHA, AMPK, mitochondria, chemotherapy, doxorubicin, tumor recurrence, metastasis, p21, apoptosis

Cellular senescence is a state in which cells permanently stop dividing but refuse to die. First described in 1961 by Leonard Hayflick and Paul Moorhead, senescence was once viewed as a simple safeguard against cancer. Scientists now understand it as a far more complex condition: senescent cells suffer mitochondrial dysfunction, oxidative stress, and DNA damage, and they secrete a potent cocktail of inflammatory and fibrotic molecules known as the senescence-associated secretory phenotype, or SASP. Factors such as interleukin-6, tumor necrosis factor alpha, and transforming growth factor beta can spread inflammation and even push neighboring cells into senescence themselves, creating a self-amplifying cycle of tissue deterioration.

In the heart, this matters enormously. Senescent cardiomyocytes—the contractile muscle cells—show impaired shortening, defective calcium handling, and resistance to apoptosis through pro-survival pathways. Senescent fibroblasts and endothelial cells contribute to fibrosis and maladaptive remodeling. Together, these changes stiffen the left ventricle, impair its relaxation, and set the stage for heart failure, particularly the diastolic form in which the heart fills poorly despite pumping adequately. Prior work had shown that senolytic drugs such as dasatinib plus quercetin, or the BCL-family inhibitor navitoclax, could clear senescent cardiac cells when given to already-aged mice, but the chronic, preventive effects of these drugs on the heart remained largely unexplored.

The research team, based at McMaster University, set out to close that gap with an unusually long experiment. They began treating twelve-month-old mice—roughly early middle age in mouse terms—with one of four regimens for nine months: a vehicle control, biweekly oral doses of dasatinib plus quercetin, twice-weekly treadmill exercise sessions, or both interventions combined. By the end of the study, the animals had reached twenty-one months of age, the threshold of old age. A separate cohort of four-month-old young mice served as a healthy benchmark. Crucially, both male and female mice were included, and the investigators reported no significant sex differences in any outcome.

The functional results were striking. Using high-frequency ultrasound, the researchers measured how quickly the left ventricle relaxed between beats—the isovolumetric relaxation time—and combined contraction and relaxation measures into the myocardial performance index, a sensitive gauge of overall cardiac health. Naturally aged control mice showed relaxation times roughly 40 percent longer and performance indices about 44 percent higher than the best-performing treatment groups, indicating substantially worse myocardial function. Exercise-treated mice also displayed a markedly better E/A ratio, a frontline marker of diastolic filling, suggesting that aerobic training preserved the ventricle’s ability to relax and fill with blood. Notably, systolic measures such as ejection fraction were largely preserved across all aged groups, reinforcing the growing view that diastolic decline, not systolic failure, is the dominant functional signature of the aging heart.

Beneath those functional improvements lay a cellular story. Using immunofluorescence to detect the canonical senescence markers p16, p21, and gamma-H2AX—a marker of DNA damage—the team counted labeled cardiomyocytes and interstitial cells across four regions of each heart. Exercise reduced p16-positive cardiomyocytes by 29 percent, senolytics by 21 percent, and the combination by 27 percent compared with aged controls. Similar reductions appeared for p21, with exercise cutting positive cardiomyocytes by nearly half, and for gamma-H2AX, where the combined intervention lowered DNA-damage-positive cells by 36 percent. Interstitial cells followed the same pattern. The researchers also found that p21 expression was highest in the central left ventricle and lower at its anterior and posterior edges, revealing a spatial heterogeneity in cardiac senescence that whole-tissue analyses can easily miss.

Perhaps the most compelling finding was correlational: across all animals, the abundance of p16- and p21-positive cells tracked closely with worse cardiac function. Higher marker levels were associated with longer relaxation times, higher myocardial performance indices, and lower cardiac output and stroke volume, with correlation coefficients reaching 0.53. Marker expression was also coordinated across cell types—p21-positive cardiomyocytes and interstitial cells correlated with a striking r of 0.91—suggesting that senescence in the aging myocardium behaves as a tissue-wide phenomenon rather than a collection of isolated bad cells. This statistical link between senescent burden and functional decline strengthens the causal plausibility of the interventions, even though correlation alone cannot prove mechanism.

The study was not without surprises. At the whole-heart level, neither exercise nor senolytics significantly reduced p16 or p21 protein expression, and mRNA results were inconsistent, with the combined group paradoxically showing elevated p53 gene expression. Canonical SASP factors measured in heart tissue and serum—using western blotting, quantitative PCR, and the sensitive Olink proteomics panel—showed no differences between young, aged, and treated animals. The authors suggest several explanations: whole-heart lysates dilute cell-specific signals, twenty-one months may be too early for a pronounced SASP surge, and cardiac cells may secrete atypical SASP profiles dominated by fibrotic and hypertrophic factors rather than classic inflammatory cytokines. The disconnect between cellular and whole-tissue measurements is itself informative, indicating that senolytic and exercise effects are most visible at the single-cell level during early old age.

Equally notable was what did not happen: combining the interventions produced no additive benefit. Exercise and senolytics each worked about as well alone as together, contradicting the researchers’ initial hypothesis. One possibility is that both interventions converge on the same downstream targets—the p16, p21, and p53 pathways and inflammatory signaling—so that once senescent cell clearance reaches a ceiling, adding a second tool yields diminishing returns. Another is that at twenty-one months, the pool of senescent cells is still moderate; exercise during the off-weeks of the intermittent senolytic schedule may have already depleted the cells that dasatinib and quercetin would otherwise have cleared. The timing of treatment relative to senescence accumulation may therefore be decisive, and the authors caution that early senolytic use could theoretically remove cardiomyocytes from a tissue with minimal regenerative capacity.

The broader implications are tantalizing. This is the first demonstration that aerobic exercise can act as a natural senolytic in the aging heart, extending earlier findings in skeletal muscle and in young animals. It is also the longest senolytic intervention yet tested in cardiac tissue, showing that preventive, rather than rescue, administration of dasatinib plus quercetin can limit senescent cell accumulation over most of a mouse’s adult life. For a rapidly aging human population facing rising rates of heart failure with preserved ejection fraction, the message is doubly appealing: one intervention is already available in every gym, while the other is advancing through the emerging field of geroscience. The authors emphasize that long-term efficacy, optimal dosing, and systemic effects must be validated before clinical translation, but the vision of preserving cardiac function by targeting the cellular biology of aging itself has moved a meaningful step closer to reality.

Subject of Research: Effects of chronic senolytic treatment and aerobic exercise on cellular senescence and myocardial function in the aging mouse heart

Article Title: Chronic Senolytic Treatment and/or Aerobic Exercise Reduce Senescence and Improve Myocardial Function During Aging in the Heart

Article References: Bevington, R. T., Johnson, A. L., Hockey, B. L., Fajardo, V. A., & Parise, G. (2026). Chronic Senolytic Treatment and/or Aerobic Exercise Reduce Senescence and Improve Myocardial Function During Aging in the Heart. Aging Cell, 25(10), Article e70759. https://doi.org/10.1111/acel.70759

Image Credits: AI Generated

DOI: 10.1111/acel.70759

Keywords: cellular senescence, senolytics, dasatinib, quercetin, aerobic exercise, aging heart, myocardial function, cardiomyocytes, SASP, diastolic function, p16, p21

The study, led by equal-contributing first authors M. Isabel Acuña and Miguel Ángel Prados, with corresponding authors Manuel Collado and Yolanda Prezado, all affiliated with the University of Santiago de Compostela in Spain, examined a technique called spatially fractionated radiotherapy, or SFRT. Unlike conventional radiotherapy, which delivers a uniform dose across the target volume, SFRT deliberately sculpts the radiation field into a pattern of high-dose peaks separated by lower-dose valleys. One implementation of this approach, known as mini-GRID, uses finely spaced beamlets to create this alternating landscape of radiation intensity. The concept may seem counterintuitive, since parts of the tumor receive a lower dose, but the geometric structure of the dose distribution appears to trigger biological responses that differ fundamentally from those produced by uniform irradiation.

To test whether this spatial patterning changes the senescence response, the researchers compared mini-GRID with conventional radiotherapy across four rodent cell models: two rat glioma cell lines, F98 and RG2, as well as immortalized rat astrocytes and primary mouse embryonic fibroblasts, which served as non-tumor comparators. The cells received single radiation doses ranging from 5 to 20 gray, a unit measuring absorbed radiation dose, and were analyzed seven days later using a battery of morphological, biochemical and molecular assays designed to detect senescence and its molecular fingerprints. This seven-day window is critical, because senescence is not an immediate consequence of radiation but a program that unfolds over days as damaged cells decide between death, repair and permanent growth arrest.

The headline result concerns the tumor cells. At the highest dose tested, 20 gray, both conventional and mini-GRID radiotherapy produced comparable reductions in glioma cell numbers, meaning the spatially fractionated approach did not sacrifice the antiproliferative effect that makes radiation effective against cancer. Yet when the researchers looked at what was happening inside the surviving cells, the two treatments told very different stories. Conventional irradiation drove the classic hallmarks of cellular senescence: the cells enlarged, a morphological signature of the senescent state, and showed increased activity of senescence-associated beta-galactosidase, a widely used enzymatic marker of senescence. After mini-GRID irradiation, both of these changes were significantly attenuated, suggesting that far fewer surviving cells had entered the senescent state.

The molecular data reinforced this picture in striking detail. Conventional radiotherapy at 20 gray triggered robust accumulation of p53, p21 and p16, proteins that form the core signaling axes governing cell-cycle arrest and senescence, along with gamma-H2AX, a phosphorylated histone variant that marks persistent DNA double-strand breaks. Mini-GRID treatment reduced the induction of all of these markers, bringing their levels close to those observed in non-irradiated controls. Quantitative PCR measurements of messenger RNA showed the same trend: the cell-cycle inhibitors encoded by the genes Cdkn1a, which produces p21, and Cdkn2a, which produces p16, were strongly upregulated by conventional irradiation but remained near baseline in mini-GRID-treated cells. In other words, the spatially fractionated dose distribution appeared to spare surviving tumor cells from the persistent DNA-damage signaling that locks them into senescence.

Perhaps most consequential for the tumor microenvironment was the effect on the SASP. Conventional irradiation elicited strong induction of four secretory genes measured in the study: Il1a, encoding the inflammatory cytokine interleukin-1 alpha; Il6, encoding interleukin-6, a pleiotropic pro-inflammatory signal; Serpine1, encoding PAI-1, a protein linked to both senescence execution and secretion; and Cxcl1, encoding a chemokine that recruits immune cells. Mini-GRID markedly blunted this response, with Il1a, Il6 and Serpine1 approaching baseline levels and Cxcl1 induction strongly reduced or nearly abolished, depending on the cell line. Because SASP factors can promote inflammation, immunosuppression and paracrine senescence in surrounding tissue, this attenuation could represent a meaningful biological advantage, though the authors note that Cxcl1 showed a more cell-line-specific response than the other factors.

Why would the same total dose, delivered in a different spatial pattern, produce such different outcomes? The researchers propose a mechanistic explanation rooted in the geometry of the dose distribution. In mini-GRID, cells lying under the high-dose peaks may sustain lethal damage and die outright, removing them from the population. Cells in the lower-dose valleys, by contrast, may accumulate sublethal damage that they can repair without fully activating the stable, self-reinforcing senescence program. Conventional uniform irradiation, by placing every cell in an intermediate dose zone, may instead maximize the population of cells that survive with enough damage to become senescent but not enough to die. The authors are careful to emphasize that this mechanism remains a proposed explanation and will require further investigation to confirm.

Importantly, the picture changed when the researchers turned to non-tumor cells. In immortalized astrocytes and primary mouse embryonic fibroblasts, radiation induced senescence in a dose-dependent manner, but no significant differences were detected between conventional and mini-GRID irradiation at matched doses. This asymmetry is notable in both directions. On one hand, mini-GRID did not exacerbate senescence in healthy cells relative to conventional treatment, which addresses a key safety concern. On the other hand, the selective sparing of senescence seen in glioma cells did not extend to the normal cell models, indicating that the decoupling of cytotoxicity from senescence is a tumor-cell-specific phenomenon under the conditions tested. As the authors put it, spatially fractionated mini-GRID radiotherapy can alter the qualitative nature of radiation-induced stress responses in tumor cells without exacerbating senescence in healthy tissues.

The findings arrive at a moment when the double-edged nature of therapy-induced senescence is commanding increasing attention in cancer biology. Senescence can act as a tumor-suppressive mechanism, halting the division of damaged cells and, in some contexts, contributing to antitumor immune responses. But persistent senescent cells and their SASP can also promote chronic inflammation, remodel tissue architecture and create niches that support tumor recurrence. A treatment modality that preserves radiation’s growth-inhibitory effect while limiting the reservoir of senescent cells and their secretory output could therefore improve the long-term therapeutic balance, particularly for brain tumors like glioma, where the tumor microenvironment plays a decisive role in progression and resistance.

Significant caveats remain, and the authors are transparent about them. The study is entirely preclinical, conducted in a limited number of rodent cell models grown in two-dimensional culture, exposed to single radiation doses, using one mini-GRID configuration and evaluated at a single seven-day time point. The experiments did not track long-term SASP dynamics, nor did they capture interactions with immune cells or other components of the tumor microenvironment that could dramatically alter the biological consequences of reduced senescence. Three-dimensional culture systems and in vivo studies will be necessary to determine whether the senescence-sparing effect persists in more physiologically relevant settings and whether it translates into better outcomes after treatment. Still, the central conclusion stands as a provocative proof of concept. As the researchers summarize, mini-GRID radiotherapy emerges as a tool capable of decoupling the cytotoxic efficacy of radiation from the induction of senescence and the SASP in tumor cells, opening a new dimension in which the spatial architecture of a radiation dose, and not merely its magnitude, becomes a tunable parameter in cancer therapy.

Subject of Research: Effects of spatially fractionated mini-GRID radiotherapy on radiation-induced cellular senescence in glioma and normal cells

Article Title: Mini-GRID radiotherapy reduces senescence while preserving growth inhibition in glioma cells

Article References: Mini-GRID radiotherapy reduces senescence while preserving growth inhibition in glioma cells. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: mini-GRID radiotherapy, spatially fractionated radiotherapy, cellular senescence, SASP, glioma, DNA damage, p21, p16, radiotherapy, tumor microenvironment, preclinical study, Aging journal

Developmental senescence differs fundamentally from the senescence associated with aging and disease. During embryogenesis, selected cells enter a transient growth-arrested state in restricted tissues at precise developmental stages. Far from being a pathological accident, this programmed arrest appears to serve constructive purposes: senescent cells secrete signaling molecules that influence neighboring tissue, help remodel embryonic structures and are then cleared, often by the embryonic immune system, once their job is done. In this sense, developmental senescence behaves like a morphogenetic regulator—a temporary scaffold that helps shape organs before being dismantled. The authors of the review capture this idea in a central formulation: developmental senescence acts as a morphogenetic regulator whose activity must be tightly integrated with proliferative cues, differentiation programs and tissue-specific signaling networks.

That integration requirement is precisely where things could go wrong. Because the program must operate at the right place, at the right time and at the right intensity, the reviewers reason that any deviation—excessive senescence, insufficient senescence, senescence that lingers too long, or senescence appearing in the wrong tissue—could interfere with normal morphogenesis. A cellular program designed to sculpt tissue could, if misregulated, deform it. This logic transforms developmental senescence from a curiosity of embryology into a plausible contributor to congenital malformations, and it sets the stage for the review’s central proposal: that CHARGE syndrome, with its distinctive constellation of developmental defects, offers an unusually good model in which to investigate that possibility.

CHARGE syndrome is a rare developmental disorder whose name summarizes its most characteristic features: coloboma of the eye, heart defects, choanal atresia (blockage of the nasal passages), growth and developmental delay, genitourinary abnormalities and characteristic ear defects. The clinical picture varies widely between patients, but the underlying genetics is comparatively straightforward. Most individuals with CHARGE syndrome carry pathogenic variants in a single gene, CHD7, which encodes an ATP-dependent chromatin remodeler—a molecular machine that uses the energy of ATP to restructure how DNA is packaged and, in doing so, regulates which genes are accessible for transcription. Chromatin remodelers sit near the top of gene-regulatory hierarchies, which helps explain why mutations in CHD7 can produce effects across so many organ systems at once.

The first pillar of the review’s argument is anatomical. The authors identify a striking three-way overlap between the tissues affected in CHARGE syndrome, the regions where CHD7 is expressed during embryonic development, and the areas where developmental senescence has been observed in experimental studies. This overlapping map includes structures associated with the eye, the inner ear, the pharyngeal regions and the nervous system—the very systems most commonly disturbed in CHARGE patients. The authors are careful to note that such spatial coincidence does not establish causality. Tissues can overlap for many reasons that have nothing to do with a shared mechanism. But the overlap provides something a hypothesis needs before it can be tested: a defined set of tissues in which to look for a functional connection between CHD7 deficiency and altered senescence.

The inner ear supplies the most compelling example in the review. Developmental senescence is known to contribute to the remodeling of the developing inner ear, a structure whose intricate geometry depends on precisely coordinated tissue sculpting. CHARGE syndrome, meanwhile, frequently involves hypoplasia or complete absence of the semicircular canals, the fluid-filled loops of the inner ear that detect rotational movement and are essential for balance. In mouse models, deficiency of Chd7—the mouse counterpart of the human gene—produces major vestibular abnormalities. Putting these observations together, the authors propose that altered senescence-related remodeling could contribute to the characteristic inner-ear defects associated with CHD7 deficiency. If the cellular program that normally refines inner-ear architecture is mis-timed or mis-located in the absence of functional CHD7, the resulting structure could be underdeveloped or absent.

The second pillar is molecular. CHD7 is not an isolated actor; the review documents its intersection with well-known pathways of cell-cycle arrest and senescence, including the p53 and p21 pathways and TGFβ-related signaling. These pathways form the canonical machinery that cells use to halt division and enter a senescent state. The experimental evidence connecting them to CHD7 is particularly intriguing. In zebrafish embryos, reduced chd7 expression causes cell-cycle arrest alongside increased expression of several cell-cycle inhibitors—the molecular fingerprint of cells being pushed toward arrest. In mouse models, inappropriate activation of p53 can produce major CHARGE-like abnormalities on its own, and, more strikingly, partially reducing the dose of Trp53, the gene encoding p53, can rescue several of the developmental defects caused by Chd7 deficiency. That rescue experiment suggests the two pathways are not merely parallel but functionally entangled: dialing down one can compensate for the loss of the other.

Evidence from other developmental models reinforces the broader principle that senescence must be precisely controlled during embryogenesis. Abnormal senescence has been implicated experimentally in models involving Six1 deficiency, exposure to the drug valproic acid, maternal diabetes and trisomy 21. In each of these contexts, developmental abnormalities appear to arise when senescence occurs in the wrong location, at the wrong time or at an inappropriate level. The review extends this logic to a wider set of congenital conditions, considering whether senescence-related mechanisms might contribute to Rett syndrome, Treacher-Collins syndrome, 22q11.2 deletion syndrome, Waardenburg syndrome and related SOX10-associated disorders, and Kallmann syndrome. Here the authors urge restraint: the evidence varies considerably among these disorders, and it remains unresolved whether the cellular changes observed in them represent authentic developmental senescence or related but distinct cell-arrest states.

The authors themselves are explicit that the connection between CHD7 and developmental senescence remains a working hypothesis. As they state, the available anatomical, developmental and molecular evidence does not yet demonstrate that CHARGE syndrome is a disorder of senescence misregulation. The evidence is heterogeneous and often indirect, assembled from different organisms, different tissues and different experimental systems. What is needed now are direct experiments: mapping senescence markers across CHD7-sensitive embryonic tissues to see whether the spatial and temporal patterns of senescence are actually disturbed when CHD7 is lost, and determining how CHD7 affects chromatin accessibility, cell-cycle control and senescence-associated signaling at the molecular level. Chromatin profiling of CHD7-deficient embryonic cells, combined with single-cell analysis of senescence markers, could reveal whether the chromatin remodeler directly regulates the genetic programs that initiate or maintain developmental senescence.

There is also a therapeutic dimension, approached with appropriate caution. Senescence-modulating approaches—drugs that clear senescent cells or suppress their secretory activity—have shown benefits in some experimental models of developmental defects. But the authors emphasize that developmental senescence is itself a normal and beneficial component of morphogenesis. Bluntly suppressing it during embryogenesis could cause as much harm as the misregulation it aims to correct. Any future intervention would need to be exquisitely targeted in time, tissue and mechanism. For now, the value of the review lies in its framing: it presents CHARGE syndrome as a candidate model for understanding how the misregulation of a normally constructive developmental program could contribute to congenital disease, linking CHD7-dependent chromatin regulation to senescence pathways and embryonic tissue remodeling. Establishing a causal role will require direct functional evidence, particularly in the CHD7-sensitive structures such as the inner ear where the anatomical, developmental and molecular threads of the hypothesis converge most tightly. If those experiments succeed, they would not only illuminate a rare syndrome but also deepen understanding of how embryos use a program usually associated with aging to build new bodies.

Subject of Research: The role of developmental senescence misregulation as a candidate mechanism in CHARGE syndrome

Article Title: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome

Article References: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: developmental senescence, CHARGE syndrome, CHD7, chromatin remodeling, morphogenesis, p53, p21, TGFβ signaling, inner ear, congenital disorders, cell-cycle arrest, embryonic development

Hepatocellular carcinoma, the most common primary liver cancer, remains one of the world’s deadliest malignancies. It is the third leading cause of cancer-related death globally, and although viral hepatitis, alcohol consumption, aflatoxin exposure and poor diet all contribute to its development, the clinical picture is dominated by a single grim statistic: most patients are diagnosed at an advanced stage, when surgical options such as resection, transplantation or ablation are no longer viable. Approved drug therapies for advanced disease, including multikinase inhibitors such as sorafenib, lenvatinib and cabozantinib, and antibody combinations built around agents like bevacizumab and atezolizumab, have extended survival only modestly. The field’s persistent hunger for molecules with new structures and new mechanisms is what makes the KGA-1002 story notable.

The compound’s origin lies in the chemistry of Artemisia, the genus that gave the world artemisinin. Sesquiterpenoid dimers, molecules in which two sesquiterpene units are joined, have repeatedly shown stronger antitumor activity than their monomeric parents, but their scarcity in plants has historically blocked serious drug development. The Kunming group sidestepped that bottleneck through biomimetic synthesis: using a Diels-Alder reaction, they assembled KGA-1002 from dehydrocostus lactone, an abundant natural sesquiterpenoid, on a ten-gram scale. The resulting dimer inhibited the proliferation of three hepatocellular carcinoma cell lines with IC50 values of 5.9, 6.9 and 6.3 micromolar against HepG2, Huh7 and SK-Hep-1 cells respectively, outperforming sorafenib and beating the parent monomer dehydrocostus lactone by roughly five- to seven-fold.

Identifying what a small molecule actually touches inside a cell is the hardest part of natural product pharmacology, and the team attacked it with a battery of orthogonal techniques. A drug affinity responsive target stability assay, which exploits the fact that ligand-bound proteins resist enzymatic digestion, flagged a protein band that survived pronase treatment only in the presence of KGA-1002. Mass spectrometry of that band yielded 49 candidate proteins, which transcriptomic profiling and bioinformatics narrowed to six. The decisive experiment was genetic: when the researchers silenced each candidate in liver cancer cells, only knockdown of GRP94, the endoplasmic reticulum-resident member of the heat shock protein 90 family, blunted the drug’s antiproliferative and anti-migratory effects. Surface plasmon resonance then measured direct binding, with a dissociation constant of 454 nanomolar, and a cellular thermal shift assay confirmed that KGA-1002 stabilizes GRP94 inside cells.

The structural detail goes further than most target-identification studies dare. KGA-1002 carries an alpha, beta-unsaturated carbonyl motif, a well-known covalent warhead, and molecular dynamics simulations showed that this group is essential for stabilizing the GRP94-ligand complex. Mass spectrometric sequencing of the treated protein revealed a peptide whose mass had increased by exactly the molecular weight of the drug, and secondary fragmentation localized the covalent bond to serine 106, a hydroxyl-bearing residue ideally positioned for nucleophilic attack on the unsaturated carbonyl. When the team mutated serine 106 to alanine, binding affinity collapsed from 522 nanomolar to 461 micromolar, a nearly thousand-fold loss. Critically, KGA-1002 did not stabilize the cytosolic family members HSP90alpha or HSP90beta, whose indiscriminate inhibition has doomed pan-HSP90 drugs in clinical trials. That isoform selectivity, aided by an additional contact with GRP94-specific asparagine 276, is arguably the compound’s most clinically relevant property.

With the target pinned down, the downstream biology fell into place. GRP94’s day job is folding, assembling and trafficking client proteins inside the endoplasmic reticulum, and its inhibition floods the ER lumen with misfolded polypeptides. Transcriptomic analysis of treated cells showed enrichment of ER-related pathways, upregulation of stress genes such as ERN1, ATF4 and DDIT3, and downregulation of ER trafficking genes. The canonical unfolded protein response sensors PERK and IRE1, normally held inactive by the chaperone BiP, were activated, driving expression and nuclear translocation of the death-promoting transcription factors XBP1 and CHOP. Because GRP94 also buffers calcium in the ER, the drug produced a dose-dependent rise in intracellular calcium, climbing to nearly 98 percent calcium-positive cells at 7.5 micromolar in both SK-Hep-1 and Huh7 lines. The unfolded protein response, in other words, was not a side effect but the engine of tumor killing.

The most novel mechanistic finding concerns AKT, the kinase at the heart of the PI3K survival pathway. KGA-1002 lowered AKT protein levels without touching its mRNA, and cycloheximide chase experiments showed the drug accelerating AKT degradation; proteasome and lysosome inhibitors each partially rescued the protein, implicating both disposal routes. The explanation proved to be a chaperone-client relationship: GRP94 physically holds AKT, and pulldown assays demonstrated that KGA-1002 disrupts that interaction, both in cell lysates and with purified proteins. Destabilized AKT could no longer phosphorylate SKP2, the F-box substrate-recognition protein of an E3 ubiquitin ligase that normally tags the cell cycle brake P21 for destruction. Deprived of AKT’s stabilizing phosphorylation, SKP2 itself was degraded through the proteasome, P21 accumulated in the nucleus, and the cells arrested in G0/G1 and died. Clinical databases reinforced the story: both GRP94 and SKP2 are overexpressed in hepatocellular carcinoma tissues and correlate with poor survival.

The death program did not stop at apoptosis. With AKT signaling crippled, the antioxidant defenses of the cell, maintained through the AKT-mTOR axis, Nrf2 and GSK-3beta, eroded, and reactive oxygen species accumulated. Mitochondrial membrane potential collapsed, lipid peroxidation measured as malondialdehyde rose, the ferroptosis gatekeeper GPX4 fell, and labile iron climbed, all hallmarks of ferroptosis, the iron-dependent form of regulated cell death. The ROS scavenger N-acetylcysteine and the ferroptosis inhibitor liproxstatin-1 each blunted these effects, confirming causality. KGA-1002 thus kills liver cancer cells along two converging routes, ER stress-driven apoptosis and AKT-dependent ferroptosis, both traceable to a single upstream lesion at GRP94.

In vivo, the compound held up. In nude mice bearing subcutaneous SK-Hep-1 tumors, intraperitoneal KGA-1002 at 15, 30 and 60 milligrams per kilogram over 60 days shrank tumors by 44.1, 52.1 and 53.5 percent, with the top dose matching sorafenib; direct intratumoral injection performed even better, reaching 61.6 percent inhibition. Tumors from treated animals showed reduced Ki67 staining and elevated phosphorylated IRE1 and PERK, confirming that the ER stress mechanism operates in living tissue. The decisive target-validation experiment came from xenografts grown from GRP94-knockdown cells: with the target partially removed, the drug’s antitumor effect and its suppression of Ki67 were significantly weakened, establishing that KGA-1002’s efficacy is GRP94-dependent. Safety readings were reassuring, with no weight loss, behavioral changes, liver or kidney function abnormalities, and no histopathological organ damage even at 150 milligrams per kilogram in a separate subacute study.

The study’s authors are careful about scope, and so should readers be. The work rests on cell lines and subcutaneous mouse models, not orthotopic liver tumors or patients, and a selectivity index of roughly 1.5 to 1.7 over normal hepatocytes, while adequate, leaves room for optimization. Yet the conceptual payoff is substantial: GRP94 has been implicated in breast cancer metastasis and multiple myeloma, and the authors note it is also overexpressed in colon, esophageal and bladder cancers, so a validated, covalent, isoform-selective inhibitor scaffold is a tool the wider oncology community can build on. By showing exactly where the molecule docks, which residue it attacks, and how that single molecular event cascades through protein folding, calcium handling, AKT stability, SKP2 degradation and ferroptosis, the Kunming team has delivered something rarer than another cytotoxic natural product: a mechanistically coherent proof that GRP94 is a druggable vulnerability in liver cancer, and a lead compound engineered to exploit it.

Subject of Research: A selective GRP94 inhibitor derived from a guaianolide sesquiterpenoid dimer as a therapeutic agent against hepatocellular carcinoma

Article Title: Guaianolide dimer KGA-1002 targets GRP94 and triggers unfolded protein response-associated degradation of SKP2/AKT axis as a novel antihepatoma agent

Article References: Li, Q.-H., Li, T.-Z., Wang, Y.-C., Huang, X.-Y., Ma, W.-J., Li, F.-J., Huang, F.-D., Hu, M.-M., & Chen, J.-J. (2026). Guaianolide dimer KGA-1002 targets GRP94 and triggers unfolded protein response-associated degradation of SKP2/AKT axis as a novel antihepatoma agent. Journal of Advanced Research, 88, 1077-1093. https://doi.org/10.1016/j.jare.2026.01.010

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.010

Keywords: hepatocellular carcinoma, GRP94, KGA-1002, guaianolide dimer, unfolded protein response, AKT, SKP2, P21, ferroptosis, endoplasmic reticulum stress, natural products, drug discovery

Bortezomib is not a new molecule. The drug, best known for its role in treating multiple myeloma and mantle cell lymphoma, works by blocking the proteasome, the cellular machinery that degrades damaged or unwanted proteins. When proteasomal degradation grinds to a halt, misfolded proteins accumulate, stress pathways ignite and cells that cannot cope are pushed into programmed death. Earlier clinical and laboratory observations had suggested that bortezomib has activity against CTCL, but the molecular wiring behind that activity had never been fully mapped. The research team, led by Kirti S. Prabhu and Shahab Uddin, set out to answer two linked questions: does bortezomib modulate SKP2-associated cell-cycle regulation in CTCL cells, and can it be combined effectively with the platinum chemotherapy drug cisplatin?

To do this, the investigators used two well-characterized human CTCL cell lines, H9 and HH, exposing them to escalating concentrations of bortezomib and measuring viability with cell counting assays, then probing the consequences with fluorescence imaging and flow cytometry. The drug proved remarkably potent. The 24-hour concentration that killed half the cells, the IC50, was just 5.25 nanomolar in H9 cells and an even lower 1.82 nanomolar in HH cells. Values in the low nanomolar range are notable because they sit comfortably within concentrations achievable in clinical practice, lending translational weight to the laboratory findings. The team then asked what kind of death the cells were dying, and the answer was unambiguous: apoptosis, the orderly suicide program that cancer cells often manage to evade.

The apoptotic signature emerged at several levels simultaneously. Flow cytometry revealed a rising sub-G0/G1 population, a classic hallmark of cells with fragmented DNA, alongside an increase in Annexin V-positive cells, which flag the externalization of phosphatidylserine, an early molecular signal of apoptosis. Immunoblotting showed activation of the caspase cascade, the proteolytic machinery that executes cell death: caspase-8, caspase-9 and caspase-3 were all cleaved into their active forms, and PARP, a DNA repair enzyme that caspase-3 slices as a finishing blow, was cleaved as well. The intrinsic, or mitochondrial, arm of apoptosis was clearly engaged, because the ratio of the pro-death protein Bax to the pro-survival protein Bcl-2 increased, and the mitochondrial membrane potential collapsed, a depolarization event that releases apoptogenic factors from the intermembrane space into the cytosol.

To confirm that this death was truly caspase-dependent, the researchers pre-treated cells with z-VAD-FMK, a broad-spectrum inhibitor that shuts down all caspases. The inhibitor significantly blunted bortezomib-induced apoptosis, demonstrating that the caspase cascade is a functional component of the drug’s cytotoxicity rather than a bystander effect. That finding matters because it anchors bortezomib’s action in a defined, druggable death pathway, one that can be monitored and potentially amplified by rational drug combinations.

Perhaps the most mechanistically revealing part of the study concerns reactive oxygen species, or ROS. Bortezomib treatment increased both cellular and mitochondrial ROS and simultaneously depleted intracellular glutathione, the cell’s principal endogenous antioxidant buffer. This double hit, more oxidants and less antioxidant capacity, creates a state of oxidative stress that damages mitochondrial membranes and feeds the apoptotic circuit. The causal contribution of ROS was tested with N-acetyl-L-cysteine, a glutathione-replenishing antioxidant. When NAC was present, bortezomib’s disruption of the cell cycle, its induction of apoptosis and its activation of caspases were all partially reduced. In other words, oxidative stress is not the whole story, but it is a genuine upstream driver of the cytotoxic program, and the partial rescue suggests that bortezomib kills CTCL cells through converging ROS-dependent and ROS-independent routes.

The study also connected bortezomib’s effects to cell-cycle control, an area where CTCL cells are particularly vulnerable. The team observed a marked suppression of SKP2, S-phase kinase-associated protein 2, an E3 ubiquitin ligase component famous for tagging the cyclin-dependent kinase inhibitors p21 and p27 for destruction. When SKP2 falls, its targets accumulate, and that is exactly what the researchers documented: levels of p21 and p27 rose while the cyclin-dependent kinases CDK4 and CDK6, which drive cells through the G1 checkpoint, declined. This SKP2-p21/p27 axis functions as a brake on proliferation, and bortezomib effectively re-engages that brake. Because SKP2 is an oncogenic driver in many lymphoid malignancies, its suppression offers a candidate pharmacodynamic vulnerability, a measurable molecular endpoint that clinicians could track to confirm that the drug is hitting its intended target in patients.

Combination therapy was the final piece of the puzzle. Platinum-based agents such as cisplatin are mainstays of oncology, but their use in CTCL is limited by toxicity and modest durable benefit. Using the Chou-Talalay method, a widely accepted mathematical framework for quantifying drug interactions through the combination index, the researchers tested whether bortezomib and cisplatin act cooperatively. At selected dose pairings, bortezomib enhanced cisplatin-induced loss of viability and apoptosis, and the interaction was strongly synergistic at 5 nanomolar bortezomib combined with 10 micromolar cisplatin. Synergy means the combination kills more cells than the sum of the two drugs acting alone, a property that could, in principle, allow lower doses of each agent and a narrower toxicity profile. The mechanistic logic is plausible: bortezomib’s ROS generation and caspase priming may lower the apoptotic threshold that cisplatin-induced DNA damage must cross to trigger cell death.

The authors are careful to frame these results as a foundation rather than a clinical verdict. All of the experiments were performed in established cell lines, and the study’s own conclusions call for validation in primary CTCL samples from patients and in in vivo models before the strategy can move toward the clinic. That caveat is standard and appropriate, yet the work still carries real significance. It converts a clinical observation, that bortezomib has activity in CTCL, into a mechanistic account involving ROS accumulation, glutathione depletion, mitochondrial depolarization, caspase activation and SKP2 pathway suppression, and it nominates a specific synergistic drug pairing for further testing. For a disease with limited durable options in its advanced stages, that combination of mechanistic depth and translational direction is exactly the kind of progress that translational medicine aims to deliver, and it gives CTCL researchers a clear set of molecular signposts to follow in the next phase of preclinical and clinical evaluation.

Subject of Research: Proteasome inhibitor bortezomib-induced ROS-dependent mitochondrial apoptosis and SKP2 signaling suppression in cutaneous T-cell lymphoma cells

Article Title: Bortezomib induces ROS-dependent mitochondrial apoptosis and suppresses SKP2 signaling in cutaneous T-cell lymphoma cells

Article References: Bortezomib induces ROS-dependent mitochondrial apoptosis and suppresses SKP2 signaling in cutaneous T-cell lymphoma cells. (n.d.). https://doi.org/10.1186/s12967-026-09039-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09039-4

Keywords: cutaneous T-cell lymphoma, bortezomib, SKP2, reactive oxygen species, mitochondrial apoptosis, caspases, p21, p27, cisplatin, proteasome inhibitor, glutathione, drug synergy

The review, led by Letícia Odaguiri Watanabe and colleagues at the University of Brasília in Brazil, followed PRISMA 2020 guidelines with a protocol registered in PROSPERO. The team searched MEDLINE/PubMed, EMBASE, Web of Science, and the Cochrane Library, supplemented by grey literature searches in Google Scholar and ProQuest and manual screening of reference lists. From 4,857 initial records, the researchers ultimately included 45 studies published between 2006 and 2025, of which 35 were purely in vitro and 10 combined laboratory and animal work. Every included study had to examine human, primary, non-genetically modified MSCs, confirm senescence with at least one established marker, and compare senescent cells against non-senescent counterparts.

A central strength of the review is its explicit framing of three distinct senescence contexts. Chronological aging reflects donor-related variability, the reality that cells from an elderly patient behave differently from those of a young one. Serial passaging captures the wear and tear inflicted during laboratory expansion, a critical manufacturing step for any cell therapy product. Inflammatory stimulation, the least studied of the three, mimics the hostile, cytokine-rich environment of chronic wounds where transplanted MSCs are expected to work. The authors argue that these contexts are biologically distinct, yet the field has rarely compared them head to head, leaving clinicians unsure which form of senescence matters most for a given therapy.

The most consistent finding across all 45 studies is a dramatic decline in proliferative capacity. Whether senescence was triggered by donor age, repeated passaging, or inflammatory stress, and regardless of whether the cells came from fat, marrow, or dental tissue, senescent MSCs divided far less readily than their youthful counterparts. The authors attribute this universal loss to the core senescence machinery, chiefly the activation of the p16 and p21 cell cycle checkpoints, which appears robustly conserved across MSC populations. In practical terms, this means aged or over-expanded cell products may simply not contain enough viable, dividing cells to mount an effective regenerative response.

Differentiation, by contrast, proved far more resilient and far more confusing. Osteogenic differentiation was variably affected: under chronological aging, roughly half of the relevant studies reported reduced bone-forming potential in adipose-derived, bone marrow-derived, and dental pulp-derived cells, but occasional studies described preserved or even enhanced osteogenesis depending on donor characteristics. Serial passaging produced similarly mixed results, with some studies reporting impaired osteogenesis and others finding no significant difference or even increased bone differentiation in late-passage cells. Adipogenic and chondrogenic outcomes ranged from functional impairment to unexpected gain-of-function, with no consistent pattern across senescence models or cell sources. The authors suggest that the multilineage differentiation program may simply be less sensitive to senescence-associated changes than the cell cycle machinery itself.

Two clinically important functions emerge as clearly senescence-sensitive. The first is migration, the ability of MSCs to home to sites of injury. Although only a handful of studies assessed it, every one that did reported impaired migratory capacity in senescent cells derived from dental pulp, bone marrow, and periodontal ligament, under both aging and passaging models. Since homing is essential for transplanted cells to reach damaged tissue, this convergence has direct implications for therapeutic efficacy. The second is immunomodulation. Senescent MSCs shift their secretory profile toward the senescence-associated secretory phenotype, or SASP, releasing pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IL-8, alongside variable changes in anti-inflammatory mediators like IL-10 and TGF-β1. Rather than uniformly losing their immunosuppressive function, senescent MSCs appear to rewire it, sometimes in ways that fuel chronic inflammation instead of resolving it.

The in vivo evidence, though sparse, points in the same troubling direction. In animal models, senescent MSCs from bone marrow, dental pulp, and periodontal ligament showed impaired mineralization, reduced bone formation, and compromised new blood vessel formation. Aged dental pulp stem cells, for example, generated significantly less pulp regeneration and vascularized tissue than young cells. The authors highlight a particularly insidious mechanism: the bystander effect, in which senescent cells secrete pro-inflammatory cytokines and reactive oxygen species that propagate senescence to neighboring healthy cells and suppress the body’s own regenerative response. In other words, a bad batch of cells may not merely fail to heal; it may actively poison the healing environment.

Why, then, has the literature been so inconsistent? The review identifies a thicket of methodological culprits. Donor age definitions vary widely, and studies that label mature adults as aged may mask the full extent of functional decline. Senescence confirmation methods differ, with SA-β-gal staining used in over 91 percent of studies, p16 expression in about half, and p21 and p53 in fewer. There are no unified thresholds for how much senescence must be present before a cell counts as senescent, and culture conditions and analysis timing vary from lab to lab. Small sample sizes and frequent reliance on qualitative or non-comparative analyses compound the problem. The authors also acknowledge a potential selection bias in their own search strategy, which relied on the historically dominant term mesenchymal stem cell rather than the currently recommended mesenchymal stromal cell, potentially missing studies that used only the latter terminology.

Risk of bias assessments add further caution. Most in vitro studies scored low overall risk using a PETRICCS-based appraisal tool, though reporting of blinding, randomization, and replicate numbers was often incomplete. The in vivo studies, evaluated with SYRCLE’s tool, showed low to moderate methodological quality, with frequent deficiencies in blinding, random housing, and selective outcome reporting. With no clinical trials included and most evidence coming from laboratory dishes, the authors stress that translational interpretation remains limited. The heterogeneity was so substantial that a quantitative meta-analysis was impossible; all results were synthesized narratively.

Nevertheless, the review’s conclusions carry real weight for the future of cell therapy. Donor age, culture expansion, and inflammatory exposure emerge as critical determinants of MSC product quality, and the authors call for standardized senescence screening, inflammatory profiling, functional quality control criteria, and defined upper passage limits for clinical-grade cells. They also urge future studies to adopt standardized senescence models, make direct comparisons across tissue sources, and prioritize in vivo models with clinically relevant endpoints, alongside strategies to prevent or reverse senescence-related decline. As the population ages and demand for regenerative therapies grows, the message is clear: the age of the cells may matter as much as the age of the patient, and ensuring that only young, vigorous MSCs reach the clinic could mean the difference between a therapy that heals and one that quietly makes things worse.

Subject of Research: Cellular senescence in mesenchymal stem/stromal cells and its impact on regenerative medicine

Article Title: Mesenchymal stem/stromal cell senescence in aging and regenerative medicine: a systematic review

Article References: Watanabe, L. O., Cardoso, L. R., Silva, J. C. D., Di Carvalho, L., Castro, V., Carvalho, J. L., Guerra, E., & Rezende, T. M. B. (2026). Mesenchymal stem/stromal cell senescence in aging and regenerative medicine: a systematic review. Biogerontology, 27(5), Article 167. https://doi.org/10.1007/s10522-026-10501-5

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10501-5

Keywords: mesenchymal stem cells, cellular senescence, SASP, aging, regenerative medicine, tissue engineering, systematic review, p16, p21, proliferation, immunomodulation, cell therapy

The investigation began with a large-scale survey of human gene expression. The team mined the Genotype-Tissue Expression database, known as GTEx, which catalogues RNA sequencing data from hundreds of donors. Comparing individuals aged 20 to 49 with those aged 60 and above across 25 tissues, they found that EYA4 expression was significantly elevated in 12 aging tissues, while remaining unchanged in the other 13. This pattern suggested that EYA4 is not a passive bystander in aging but a gene whose expression is actively remodeled as organisms grow older, echoing a growing appreciation that senescence-associated genes can feed back to regulate the aging trajectory itself.

To connect that tissue-level observation to a cellular mechanism, the researchers turned to primary human diploid fibroblasts, the classic workhorse of senescence research. They generated replicatively senescent HFF-1 and BJ fibroblasts by culturing them beyond 50 population doublings, roughly double the lifespan of young control cells at about 25 doublings. They also induced senescence chemically, treating young fibroblasts with bleomycin, a DNA-damaging agent, for three days. In both models, senescence was confirmed by elevated senescence-associated beta-galactosidase activity and increased p21, a cyclin-dependent kinase inhibitor that serves as a canonical senescence marker. Crucially, EYA4 rose in parallel, at both the messenger RNA and protein levels, in every senescent culture examined.

The functional test followed. Using small interfering RNAs to knock down EYA4 in fibroblasts approaching replicative senescence, the team observed a striking rescue: levels of p21 and senescence-associated beta-galactosidase dropped, and EdU incorporation assays showed that many cells retained their capacity to synthesize DNA and divide. The same held true in bleomycin-induced senescence, where EYA4 depletion again reduced senescence markers and preserved proliferative capacity. Together, these experiments demonstrated that EYA4 is not merely correlated with senescence but actively promotes it, and that removing it can delay both the replicative and stress-induced forms of the process.

What made this result mechanistically intriguing is that EYA4 is an unusual protein with two distinct biochemical faces. Its C-terminal Eya domain carries tyrosine phosphatase activity and mediates protein interactions, while its N-terminal domain harbors threonine phosphatase activity and transcriptional co-activation functions. To determine which activity drives p21 upregulation, the researchers engineered phosphatase-deficient mutants targeting each domain separately. Remarkably, both mutants promoted p21 expression just as strongly as wild-type EYA4. The senescence-promoting function of EYA4 therefore depends not on its enzymatic phosphatase activity but on its transcriptional activation capacity, a distinction that matters because it narrows the search for the relevant molecular partners.

That search led to SIX2, a transcription factor from the SIX family, whose members are famous for partnering with EYA proteins during development. Because EYA proteins lack any intrinsic DNA-binding ability, they depend on SIX partners to be escorted into the nucleus and tethered to specific promoters. Mining GTEx data through the GEPIA platform, the team found that SIX1, SIX2 and SIX4 expression correlated positively with EYA4 across tissues, and that SIX2 was the most abundantly expressed of the three in the 12 tissues where EYA4 rises with age, as well as in HeLa cells used for mechanistic assays. Co-immunoprecipitation experiments then confirmed that EYA4 and SIX2 physically interact, with the Eya domain of EYA4 serving as the primary binding interface.

The partnership proved functionally essential. Immunofluorescence microscopy showed that SIX2 overexpression drove EYA4 into the nucleus, while SIX2 knockdown diminished EYA4’s nuclear localization. Overexpressing SIX2 alone increased p21, but silencing SIX2 abolished EYA4’s ability to boost p21, and conversely, silencing EYA4 negated SIX2’s effect. Chromatin immunoprecipitation followed by quantitative PCR revealed that SIX2 binds to the P21 promoter within roughly one kilobase upstream of the transcription start site, and dual-luciferase reporter assays confirmed that this binding region is sufficient to activate P21 transcription. The model that emerges is one of mutual dependence: SIX2 recruits EYA4 to DNA, and EYA4 supplies the transcriptional activation power that neither protein can provide alone.

The p53 connection added a final layer of complexity. p53, the famed tumor suppressor, binds the P21 promoter about 2.4 kilobases upstream of the transcription start site and is classically regarded as p21’s master regulator. When the researchers generated p53-knockout HeLa cells using CRISPR, p21 expression fell to undetectable levels, and neither EYA4 nor SIX2 overexpression could restore it. Rescuing p53 in those cells brought p21 back to normal, and EYA4 knockdown then reduced p21 and senescence-associated secretory phenotype factors as before. Importantly, further experiments showed that p53 does not disrupt the EYA4-SIX2 interaction itself, nor does it prevent SIX2 from binding the P21 promoter, and the promoter remained responsive to p53-independent activation by an AKT inhibitor. This suggests p53 acts as a permissive gatekeeper for transcriptional initiation while the EYA4-SIX2 complex fine-tunes expression levels, though the authors caution that the precise mechanism requires further study.

The study’s implications extend in several directions. Because p21 is persistently activated in replicative and DNA damage-induced senescence, and elevated p21 has been linked to metabolic and cardiovascular diseases, the EYA4-SIX2 axis offers a candidate target for interventions aimed at delaying age-related pathology. The researchers also note that EYA4 plays dual roles in cancer, promoting some tumors through its phosphatase activity while suppressing others, so any therapeutic strategy would need to account for context. Open questions remain, including whether EYA4 partners with other SIX family members in different tissues, whether the axis also governs developmentally programmed senescence, and whether the complex preferentially regulates early-stage rather than late-stage senescence. The authors acknowledge the absence of endogenous co-immunoprecipitation data, owing to antibody limitations, but point to structural studies of related EYA-SIX complexes as strong support for a direct interaction. As senescence research moves from correlation toward mechanism, EYA4’s emergence as a p53-dependent, phosphatase-independent driver of p21 transcription offers a fresh and testable entry point into the biology of growing old.

Subject of Research: The role of EYA4 and SIX2 in regulating p21 transcription and cellular senescence during aging

Article Title: EYA4 promotes cellular senescence by enhancing P21 transcription through interaction with SIX2

Article References: Li, X., Mao, P., Chen, D., Li, L., Fang, H., Huang, J., & Liu, H. (2026). EYA4 promotes cellular senescence by enhancing P21 transcription through interaction with SIX2. Advanced Biotechnology, 4(2), Article 17. https://doi.org/10.1007/s44307-026-00109-8

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00109-8

Keywords: EYA4, SIX2, p21, cellular senescence, p53, aging, GTEx, transcriptional regulation, phosphatase, fibroblasts, gene expression, senescence markers